# Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

> **NCT03869762** · PHASE2 · TERMINATED · sponsor: **Cancer Trials Ireland** · enrollment: 7 (actual)

## Conditions studied

- Castration-resistant Prostate Cancer
- Metastatic Cancer
- Bone Metastases

## Interventions

- **DRUG:** Xgeva
- **DRUG:** Xtandi

## Key facts

- **NCT ID:** NCT03869762
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-09
- **Primary completion:** 2019-01-12
- **Final completion:** 2019-01-12
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Insufficient accrual
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03869762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03869762, "Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03869762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*